Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)

被引：150

作者：

Powell, Chelsea E. ^{[1
,4
]}

Gao, Yang ^{[5
,6
]}

Tan, Li ^{[1
,4
]}

Donovan, Katherine A. ^{[1
,4
]}

Nowak, Radoslaw P. ^{[1
,4
]}

Loehr, Amanda ^{[5
,6
]}

Bahcall, Magda ^{[2
]}

Fischer, Eric S. ^{[1
,4
]}

Janne, Pasi A. ^{[2
,3
]}

George, Rani E. ^{[5
,6
]}

Gray, Nathanael S. ^{[1
,4
]}

机构：

[1] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA

[3] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA 02215 USA

[4] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA

[5] Harvard Med Sch, Dept Pediat Hematol & Oncol, Dana Farber Canc Inst, Boston, MA 02215 USA

[6] Harvard Med Sch, Childrens Hosp Boston, Boston, MA 02215 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2018年 / 61卷 / 09期

基金：

美国国家卫生研究院;

关键词：

CELL LUNG-CANCER; INHIBITOR; RESISTANCE; POTENT;

D O I：

10.1021/acs.jmedchem.7b01655

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We present the development of the first small molecule degraders that can induce anaplastic lymphoma kinase (ALK) degradation, including in non-small-cell lung cancer (NSCLC), anaplastic large-cell lymphoma (ALCL), and neuroblastoma (NB) cell lines. These degraders were developed through conjugation of known pyrimidine-based ALK inhibitors, TAE684 or LDK378, and the cereblon ligand pomalidomide. We demonstrate that in some cell types degrader potency is compromised by expression of drug transporter ABCB1. In addition, proteomic profiling demonstrated that these compounds also promote the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).

引用

页码：4249 / 4255

页数：7

共 50 条

[1] Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC)
Kang, Chung Hyo
Lee, Dong Ho
Lee, Chong Ock
Ha, Jae Du
Park, Chi Hoon
Hwang, Jong Yeon
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 505 (02) : 542 - 547
[2] Anaplastic lymphoma kinase (ALK) in rhabdomyosarcoma.
van Gaal, J. C.
Flucke, U. E.
Roeffen, M. H. S.
de Bont, E. S.
Suurmeijer, A. J.
van der Graaf, W. T.
Versleijen-Jonkers, Y. M. H.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] Implications of ALK (anaplastic lymphoma kinase) in oncohematology
Cluzeau, T.
Pecuchet, N.
Mounier, N.
Vignot, S.
BULLETIN DU CANCER, 2010, 97 (08) : 991 - 996
[4] Translocations involving anaplastic lymphoma kinase (ALK)
Duyster, J
Bai, RY
Morris, SW
ONCOGENE, 2001, 20 (40) : 5623 - 5637
[5] Translocations involving anaplastic lymphoma kinase (ALK)
Justus Duyster
Ren-Yuan Bai
Stephan W Morris
Oncogene, 2001, 20 : 5623 - 5637
[6] Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement
Khanlari, Mahsa
Tang, Guilin
Hao, Suyang
Gong, Yun
Li, Shaoying
Miranda, Roberto N.
Lin, Pei
Iyer, Swaminathan
Yin, Cameron C.
Xie, Wei
Vega, Francisco
Medeiros, L. J.
Xu, Jie
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (01) : E17 - E21
[7] Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer
Ou, Sai-Hong Ignatius
Shirai, Keisuke
LUNG CANCER AND PERSONALIZED MEDICINE: CURRENT KNOWLEDGE AND THERAPIES, 2016, 893 : 179 - 187
[8] Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
Kong, Xiaotian
Pan, Peichen
Sun, Huiyong
Xia, Hongguang
Wang, Xuwen
Li, Youyong
Hou, Tingjun
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (24) : 10927 - 10954
[9] Status of Anaplastic Lymphoma Kinase (ALK) in Malignant Mesothelioma
Varesano, Serena
Leo, Claudio
Boccardo, Simona
Salvi, Sandra
Truini, Mauro
Ferro, Paola
Fedeli, Franco
Canessa, Pier Aldo
Dessanti, Paolo
Pistillo, Maria Pia
Roncella, Silvio
ANTICANCER RESEARCH, 2014, 34 (05) : 2589 - 2592
[10] ANAPLASTIC LYMPHOMA KINASE INHIBITION ACTIVATES AUTOPHAGY IN ALK plus ANAPLASTIC LARGE CELL LYMPHOMA
Hoogstra, D.
Buelow, K.
Vettukattil, T.
Poole, G.
Fountain, M.
Martin, K.
Lim, M.
MacKeigan, J.
LEUKEMIA RESEARCH, 2022, 121 : S67 - S68

← 1 2 3 4 5 →